Enter your information to receive a comprehensive mesothelioma packet free of charge at your doorstep within 24 hours.
Mesothelioma Treatment | Leading Physicians
Dr. David Sugarbaker – Boston, Massachusetts
Overview
Dr. David Sugarbaker is a world-renowned board certified thoracic surgeon and originator of the “tri-modal” approach to treating malignant pleural mesothelioma. His current leadership appointments include Chief of Thoracic Surgery at Brigham and Women's Hospital, Chief of Surgical Services at the Dana-Farber Cancer Institute, Executive Vice-Chair, Department of Surgery at Brigham and Women's Hospital, and Professor of Surgery at Harvard Medical School.
Educational Background
Dr. Sugarbaker first graduated from Wheaton College in Illinois and subsequently graduated from Cornell University Medical College in 1979. He completed residencies at several hospitals including Peter Bent Brigham Hospital, Brigham and Women’s Hospital, Toronto General Hospital, and Hospital for Sick Children, University of Toronto.
Clinical and Laboratory Research
Dr. Sugarbaker is considered to be one of the world’s leading experts in the diagnosis and treatment of malignant pleural mesothelioma, a type of lung cancer that is often related to asbestos exposure. In fact, the majority of Dr. Sugarbaker’s clinical and laboratory research has centered on the development of what has been termed a “tri-modal” therapeutic approach to treating malignant pleural mesothelioma. This three-pronged approach uses a combination of radical surgery (removal of a large portion of the lining of the lung and sometimes parts of the lung itself), chemotherapy and radiation therapy to treat victims of pleural mesothelioma. Highly regarded in his field, Dr. Sugarbaker’s research and experience has significantly improved survival rates among those diagnosed with malignant pleural mesothelioma.
In an effort to address the growing number of mesothelioma cases worldwide, Dr. David Sugarbaker, MD founded the International Pleural Mesothelioma Program. The program is comprised of both a clinical arm and research arm that, together, are focused on developing new and more effective treatment protocols designed to improve the life expectancy of individuals diagnosed with malignant pleural mesothelioma.
Dr. Sugarbaker’s research and clinical experience with innovative treatment therapies for pleural malignant mesothelioma has earned him recognition at both national and international levels. He travels worldwide to deliver lectures on the topic of mesothelioma treatment and has been published in numerous medical journals and textbooks.
Relevant Articles by Dr. David Sugarbaker
Phase I to II Study of Pleurectomy/Decortication and Intraoperative Intracavitary Hyperthermic Cisplatin Lavage for Mesothelioma - Journal of Clinical Oncology, Vol 24, No 10 (April 1), 2006: pp. 1561-1567
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies - J Thorac Cardiovasc Surg 2004;128:138-146
Pleural Biopsy: A Reliable Method for Determining the Diagnosis But Not Subtype in Mesothelioma - Ann Thorac Surg 2004;78:1774-1776
Resection margins, extrapleural nodal status, and cell type determine postoperativ long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients - J Thorac Cardiovasc Surg 1999;117:54-65
Pleuropneumonectomy in the treatment of malignant pleural mesothelioma. - Chest. 1999 Dec;116(6 Suppl):450S-454S.
Extrapleural pneumonectomy in the setting of multimodality therapy for diffuse malignant pleural mesothelioma. - Semin Thorac Cardiovasc Surg. 1997 Oct;9(4):373-82
Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma. - J Thorac Cardiovasc Surg. 1991 Jul;102(1):10-4; discussion 14-5
